Current status and future directions of post-marketing vaccine safety monitoring with focus on USA and Europe

Biologicals

Volumn 40, Issue 5, 2012, Pages 393-397

  Bonhoeffer, Jan ^a,b   Black, Steve ^c   Izurieta, Hector ^d   Zuber, Patrick ^e   Sturkenboom, Miriam ^f  

^a Brighton Collaboration Foundation   (Switzerland)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Monitoring; Pharmacovigilance; Vaccine safety

Indexed keywords

INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE;

ARTICLE; DISEASE ASSOCIATION; DRUG RESPONSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPE; EVIDENCE BASED MEDICINE; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNIZATION; NARCOLEPSY; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; THROMBOCYTOPENIA; UNITED STATES; VACCINATION;

EUROPE; HUMANS; MODELS, BIOLOGICAL; PATIENT SAFETY; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES; VACCINATION; VACCINES;

EID: 84865615028     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2012.07.007     Document Type: Article

References (24)

1. Duclos P., Okwo-Bele J.M., Gacic-Dobo M., Cherian T. Global immunization: status, progress, challenges and future. BMC Int Health Hum Rights 2009, 9(Suppl. 1):S2.
2. World Health Organization - Unicef. Global immunization vision and strategy 2006-2015. -WHO/IVB/05.05: Available at: http://www.who.int/vaccines-documents/docspdf05/givs_final_en.pdf.
3. Kwok R. Vaccines: the real issues in vaccine safety. Nature 2011, 473(7348):436-438.
4. Bonhoeffer J., Heininger U. Adverse events following immunization: perception and evidence. Curr Opin Infect Dis 2007, 20(3):237-246.
5. Chen R.T., Rastogi S.C., Mullen J.R., Hayes S.W., Cochi S.L., Donlon J.A., et al. The vaccine adverse event reporting system (VAERS). Vaccine 1994, 12(6):542-550.
6. Bonhoeffer J., Kohl K., Chen R., Duclos P., Heijbel H., Heininger U., et al. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 2002, 21(3-4):298-302.
7. World Health Organization WHO consultation on global monitoring of adverse events following immunization, 9-10 January 2006. Weekly Epidemiological Record/Health Section of the Secretariat of the League of Nations 2006, 81(27):261-265.
8. Stang P.E., Ryan P.B., Racoosin J.A., Overhage J.M., Hartzema A.G., Reich C., et al. Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann Intern Med 2010, 153(9):600-606.
9. Coloma P.M., Schuemie M.J., Trifiro G., Gini R., Herings R., Hippisley-Cox J., et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf 2011, 20(1):1-11.
10. Lieu T.A., Kulldorff M., Davis R.L., Lewis E.M., Weintraub E., Yih K., et al. Real-time vaccine safety surveillance for the early detection of adverse events. Med Care 2007, 45(10 Suppl 2):S89-S95.
11. Brighton_Collaboration. Vaccine safety resources. 2011; Available from: https://brightoncollaboration.org/public/resources.html.
12. Brighton Collaboration Automated case classification tool 2011, Brighton Collaboration, Available from. https://brightoncollaboration.org/public/resources/abc-tool.html.
13. Andrews N, Stowe J, Miller L, Svanstrom H, Johansen K, J B, et al. A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark 2011.
14. Dieleman J, Romio S, K. J, Weibel D, Bonhoeffer J, Sturkenboom M, et al. Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines-a multinational case-control study in Europe. 2011.
15. LaRussa P.S., Edwards K.M., Dekker C.L., Klein N.P., Halsey N.A., Marchant C., et al. Understanding the role of human variation in vaccine adverse events: the clinical immunization safety assessment network. Pediatrics 2011, 127(Suppl. 1):S65-S73.
16. World Health Organization Challenges in global immunization and the global immunization vision and strategy 2006-2015. Wkly Epidemiol Rec 2006, 81(19):190-195.
17. Poland G.A. Vaccidents and adversomics. Vaccine 2010, 28(40):6549-6550.
18. Poland G.A., Ovsyannikova I.G., Jacobson R.M. Adversomics: the emerging field of vaccine adverse event immunogenetics. Pediatr Infect Dis J 2009, 28(5):431-432.
19. EuropeanMedicinesAgency. EudraVigilance. Available from: http://eudravigilance.ema.europa.eu/human/index.asp.
20. Chen R.T., Glasser J.W., Rhodes P.H., Davis R.L., Barlow W.E., Thompson R.S., et al. Vaccine safety datalink project: a new tool for improving vaccine safety monitoring in the United States. The vaccine safety datalink team. Pediatrics 1997, 99(6):765-773.
21. Baggs J., Gee J., Lewis E., Fowler G., Benson P., Lieu T., et al. The vaccine safety datalink: a model for monitoring immunization safety. Pediatrics 2011, 127(Suppl. 1):S45-S53.
22. Behrman R.E., Benner J.S., Brown J.S., McClellan M., Woodcock J., Platt R. Developing the sentinel system-a national resource for evidence development. N Engl J Med 2011, 364(6):498-499.
23. VaccineAdverseEventSurveillanceandCommunication(VAESCO)Network. Available from: http://vaesco.net.
24. Valenciano M., Kissling E., Cohen J.M., Oroszi B., Barret A.S., Rizzo C., et al. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Med 2011, 8(1):e1000388.